Avicanna Inc (AVCN.TO) has seen a notable decline this week amidst a backdrop of recent company developments.
Avicanna Inc, a Canadian biopharmaceutical company focused on cannabinoid-based products, has experienced a 7.41% drop in stock price over the past week, closing at C$0.13. Despite recent company news, the stock has struggled to maintain momentum.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Avicanna Inc
AVCN.TO
AVCN.TO
Avicanna Inc
WealthAwesomeMarket cap
$15.72M
52W high
$0.30
52W low
$0.10
1W change
-7.41%
Beta
0.33
Analyst Price Targets
Based on analyst covering AVCN
Wall Street analysts forecast AVCN stock price to rise 460.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.70
+460.0% Upside
Current Price
C$0.13
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AVCN's historical volatility
30-Day Vol
70.3%
Annualized
90-Day Vol
65.4%
Annualized
Trend (90d)
-47.6%
Annualized drift
90d Mean
C$0.11
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.12 | C$0.09 – C$0.15 |
| 60 trading days | C$0.11 | C$0.08 – C$0.16 |
| 90 trading days | C$0.11 | C$0.07 – C$0.16 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider the recent performance of Avicanna amidst its strategic developments, including product launches and leadership changes, while also keeping an eye on market trends in the health care sector.
Avicanna's stock has seen a YTD decline of 43.18%.
Despite a bullish average analyst target of C$0.70, the current performance reflects significant volatility and investor skepticism.
Bull case
The launch of the QUIX™ rapid-onset medical cannabis portfolio and a strategic investment from Splash Beverage Group could open up growth opportunities for Avicanna in the expanding medical cannabis market.
Bear case
The stock's significant drop this week, along with its performance below both the 50-day and 200-day moving averages, may raise concerns about the company's short-term viability and investor confidence.
Recent Price Action
Advertisement
Avicanna Inc's stock (AVCN.TO) closed at C$0.13, reflecting a 7.41% decrease over the past week. This decline follows a year-to-date drop of 43.18%, indicating ongoing challenges for the company in regaining investor confidence.
Company Developments
Despite the stock's recent struggles, Avicanna has been active in expanding its product offerings. The recent launch of the QUIX™ rapid-onset medical cannabis portfolio aims to strengthen its position in the medical cannabis market. Additionally, the appointment of Nick Hilborn as Chief Financial Officer is intended to enhance financial leadership as the company navigates its growth strategy.
Technical Picture
From a technical standpoint, Avicanna's stock is currently trading below its 50-day moving average of C$0.13 and its 200-day moving average of C$0.18, indicating a bearish trend. The stock has a 52-week range of C$0.10 – C$0.30, currently at 15% of that range. With a beta of 0.33, the stock exhibits lower volatility compared to the broader market. Recent trading volume has been low, with 27,657 shares changing hands, significantly below the 20-day average volume of 108,705 shares.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
